Cargando…

Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions

BACKGROUND: Biologic and targeted synthetic disease modifying agents (b/tsDMARDs) have broadened the treatment landscape for autoimmune diseases particularly in patients refractory to conventional DMARDs. More recently, the introduction of biosimilars has reduced the price of bDMARDs, potentially im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khoo, Thomas, Sidhu, Navkiran, Marine, Franca, Lester, Susan, Quinlivan, Alannah, Rowett, Debra, Buchbinder, Rachelle, Hill, Catherine L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783393/ https://www.ncbi.nlm.nih.gov/pubmed/36550585 http://dx.doi.org/10.1186/s41927-022-00309-4

Ejemplares similares

Attitudes of Australians with inflammatory arthritis to biologic therapy and biosimilars
por: Quinlivan, Alannah, et al.
Publicado: (2022)

Vaccination Rates, Perceptions, and Information Sources Used by People With Inflammatory Arthritis
por: Lyon, Andrea, et al.
Publicado: (2023)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis
por: Venter, Gabriella, et al.
Publicado: (2021)

Task force greener gastroenterology: Towards eco‐friendly practices in healthcare
por: Duijvestein, Marjolijn, et al.
Publicado: (2023)

Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Bernasko, Nana, et al.
Publicado: (2021)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

European guidelines on functional bowel disorders with diarrhoea: United European Gastroenterology (UEG) and European Society for neurogastroenterology and motility (ESNM) statements and recommendations
por: Tornkvist, Navkiran T., et al.
Publicado: (2022)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Joint Canadian Association of Gastroenterology and Crohn’s Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease
por: Moayyedi, Paul, et al.
Publicado: (2019)

Editorial Review for: Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Hanson, Karen
Publicado: (2021)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Biosimilar medicines – their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in Gastroenterology
por: Mularczyk, Aldona, et al.
Publicado: (2014)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
por: Fleischmann, Roy, et al.
Publicado: (2020)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

Attitudes and practices in the laboratory monitoring of conventional synthetic disease modifying anti-rheumatic drugs by rheumatologists and rheumatology trainees
por: Tsakas, James J., et al.
Publicado: (2022)

Improving the quality use of highly specialised drugs
por: Hill, Catherine L, et al.
Publicado: (2021)

GASTROENTEROLOGY
Publicado: (1982)

GASTROENTEROLOGY
Publicado: (1972)

Gastroenterology
Publicado: (2011)

Gastroenterology
por: Davies, E. Rhys
Publicado: (1992)

Gastroenterology
por: Chopra, Angeli
Publicado: (2015)

Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
por: Cohen, Hillel, et al.
Publicado: (2016)

Physicians’ perceptions of the uptake of biosimilars: a systematic review
por: Sarnola, Kati, et al.
Publicado: (2020)

“Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients' perceptions of biosimilars
por: Varma, Meera, et al.
Publicado: (2022)

Imbalanced machine learning classification models for removal biosimilar drugs and increased activity in patients with rheumatic diseases
por: Castro Corredor, David, et al.
Publicado: (2023)

Multimorbidity in rheumatic conditions
por: Radner, Helga
Publicado: (2016)

Latent Rheumatic Conditions
por: Phelan, J. R.
Publicado: (1906)

Gastroenterologic endoscopy
por: Sivak, Michael V.
Publicado: (1987)

Textbook of gastroenterology
Publicado: (1995)

Gastroenterology and hepatology /
Publicado: (1999)

PROBLEMS IN GASTROENTEROLOGY
Publicado: (1983)

POSTGRADUATE GASTROENTEROLOGY
Publicado: (1967)

Clinical Gastroenterology
por: Mandell, Harvey
Publicado: (1970)

Clinical Gastroenterology
por: Drennan, Fred Miller
Publicado: (1985)

Atlas of gastroenterology /
Publicado: (1992)

Imaging in Gastroenterology
por: Badea, Radu, et al.
Publicado: (2014)

The Advance of Gastroenterology
por: Naish, J. M.
Publicado: (1966)

Rabbit Gastroenterology
por: Reusch, Brigitte
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_vsj9frdf8mg4taro8u8isici0g